NCT06193889 2026-05-15KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia GravisKyverna TherapeuticsPhase 2/3 Recruiting66 enrolled